Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial by Todd, J et al.
RESEARCH ARTICLE
Regulatory T Cell Responses in Participants
with Type 1 Diabetes after a Single Dose of
Interleukin-2:A Non-Randomised,Open
Label, Adaptive Dose-FindingTrial
John A. Todd1¤a*, Marina Evangelou2☯, Antony J. Cutler1☯¤a, Marcin L. Pekalski1☯¤a, Neil
M. Walker1☯, Helen E. Stevens1☯, Linsey Porter1, Deborah J. Smyth1, Daniel B. Rainbow1¤a,
Ricardo C. Ferreira1¤a, Laura Esposito1, Kara M. D. Hunter1, Kevin Loudon1, Kathryn Irons3,
Jennie H. Yang4, Charles J. M. Bell1, Helen Schuilenburg1, James Heywood1, Ben Challis5,
Sankalpa Neupane5, Pamela Clarke1, Gillian Coleman1, Sarah Dawson1, Donna Goymer1,
Katerina Anselmiova1, Jane Kennet1, Judy Brown1, Sarah L. Caddy6, Jia Lu6,
Jane Greatorex7, Ian Goodfellow6, Chris Wallace1,8, Tim I. Tree4, Mark Evans5, Adrian
P. Mander8, Simon Bond3,8, Linda S. Wicker1¤a, Frank Waldron-Lynch1¤b*
1 JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics,
Cambridge Institute for Medical Research, National Institute for Health Research Cambridge Biomedical
Research Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom,
2 Department of Mathematics, Imperial College London, London, United Kingdom, 3 National Institute for
Health Research Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust,
Cambridge Biomedical Campus, Cambridge, United Kingdom, 4 Department of Immunobiology, Faculty of
Life Sciences & Medicine, King’s College London, National Institute of Health Research Biomedical
Research Centre, Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College
London, London, United Kingdom, 5 Wellcome Trust/MRC Institute of Metabolic Science, National Institute
for Health Research Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge,
United Kingdom, 6 Division of Virology, Department of Pathology, Addenbrooke’s Hospital, Cambridge
Biomedical Campus, University of Cambridge, Cambridge, United Kingdom, 7 Public Health England,
Clinical Microbiology and Public Health Laboratory, Addenbrooke’s Hospital, Cambridge University Hospitals
NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom, 8 MRC Biostatistics
Unit Hub for Trials Methodology Research, Cambridge Institute of Public Health, Cambridge Biomedical
Campus, Cambridge, United Kingdom
☯ These authors contributed equally to this work.
¤a Current address: Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
University of Oxford, Oxford, United Kingdom
¤b Current address: Experimental Medicine and Immunotherapeutics, Department of Medicine, School of
Clinical Medicine, National Institute for Health Research Cambridge Biomedical Research Centre,
Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
* fw211@cam.ac.uk (FWL); john.todd@well.ox.ac.uk (JAT)
Abstract
Background
Interleukin-2 (IL-2) has an essential role in the expansion and function of CD4+ regulatory T
cells (Tregs). Tregs reduce tissue damage by limiting the immune response following infec-
tion and regulate autoreactive CD4+ effector T cells (Teffs) to prevent autoimmune dis-
eases, such as type 1 diabetes (T1D). Genetic susceptibility to T1D causes alterations in
the IL-2 pathway, a finding that supports Tregs as a cellular therapeutic target. Aldesleukin
(Proleukin; recombinant human IL-2), which is administered at high doses to activate the
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immune system in cancer immunotherapy, is now being repositioned to treat inflammatory
and autoimmune disorders at lower doses by targeting Tregs.
Methods and Findings
To define the aldesleukin dose response for Tregs and to find doses that increase Tregs
physiologically for treatment of T1D, a statistical and systematic approach was taken by
analysing the pharmacokinetics and pharmacodynamics of single doses of subcutaneous
aldesleukin in the Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes
(DILT1D), a single centre, non-randomised, open label, adaptive dose-finding trial with 40
adult participants with recently diagnosed T1D. The primary endpoint was the maximum
percentage increase in Tregs (defined as CD3+CD4+CD25highCD127low) from the baseline
frequency in each participant measured over the 7 d following treatment. There was an ini-
tial learning phase with five pairs of participants, each pair receiving one of five pre-
assigned single doses from 0.04 × 106 to 1.5 × 106 IU/m2, in order to model the dose-
response curve. Results from each participant were then incorporated into interim statistical
modelling to target the two doses most likely to induce 10% and 20% increases in Treg fre-
quencies. Primary analysis of the evaluable population (n = 39) found that the optimal
doses of aldesleukin to induce 10% and 20% increases in Tregs were 0.101 × 106 IU/m2
(standard error [SE] = 0.078, 95% CI = −0.052, 0.254) and 0.497 × 106 IU/m2 (SE = 0.092,
95% CI = 0.316, 0.678), respectively. On analysis of secondary outcomes, using a highly
sensitive IL-2 assay, the observed plasma concentrations of the drug at 90 min exceeded
the hypothetical Treg-specific therapeutic window determined in vitro (0.015–0.24 IU/ml),
even at the lowest doses (0.040 × 106 and 0.045 × 106 IU/m2) administered. A rapid
decrease in Treg frequency in the circulation was observed at 90 min and at day 1, which
was dose dependent (mean decrease 11.6%, SE = 2.3%, range 10.0%–48.2%, n = 37),
rebounding at day 2 and increasing to frequencies above baseline over 7 d. Teffs, natural
killer cells, and eosinophils also responded, with their frequencies rapidly and dose-depen-
dently decreased in the blood, then returning to, or exceeding, pretreatment levels. Further-
more, there was a dose-dependent down modulation of one of the two signalling subunits
of the IL-2 receptor, the β chain (CD122) (mean decrease = 58.0%, SE = 2.8%, range
9.8%–85.5%, n = 33), on Tregs and a reduction in their sensitivity to aldesleukin at 90 min
and day 1 and 2 post-treatment. Due to blood volume requirements as well as ethical and
practical considerations, the study was limited to adults and to analysis of peripheral blood
only.
Conclusions
The DILT1D trial results, most notably the early altered trafficking and desensitisation of
Tregs induced by a single ultra-low dose of aldesleukin that resolves within 2–3 d, inform
the design of the next trial to determine a repeat dosing regimen aimed at establishing a
steady-state Treg frequency increase of 20%–50%, with the eventual goal of preventing
T1D.
Trial Registration
ISRCTN Registry ISRCTN27852285; ClinicalTrials.gov NCT01827735
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Author Summary
Why Was This Study Done?
• Insulin replacement, the only approved therapy for the treatment of type 1 diabetes
(T1D), treats the symptoms but not the underlying cause of the disease, namely,
immune-mediated destruction of the insulin-producing β cells of the pancreas.
• Aldesleukin, recombinant interleukin-2 (IL-2), was selected as a candidate immunother-
apy to prevent or delay autoimmunity because previous genetic and phenotypic analyses
indicate a major role for the IL-2 pathway in the development of T1D.
• IL-2 is critical for maintaining the function of the regulatory T cells (Tregs) that prevent
autoimmunity. Therefore, the first step in our approach to T1D prevention was to deter-
mine the single doses of aldesleukin that increase Treg numbers within the physiological
range, aiming to mimic the protection against T1D afforded by the risk-reducing alleles
of the IL-2 pathway.
What Did the Researchers Do and Find?
• We successfully employed a state-of-the-art dose-finding, open label, adaptive clinical
trial design in 40 participants with T1D to determine the doses of aldesleukin needed to
raise Treg frequencies by 10% and 20%.
• Increased Treg frequencies induced by aldesleukinwere preceded by a peak of aldesleu-
kin in the blood at 90 minutes that caused a transient dose-dependent decrease of Tregs
and other cell subsets in the circulation.
• Following treatment with a dose of aldesleukin, Tregs had a decreased sensitivity to IL-2
that returned to baseline on day 3 after treatment.
What Do These Findings Mean?
• The DILT1D trial showed that it is possible to conduct an adaptive dose-finding trial to
estimate two drug doses based on an immune cell biomarker as a primary outcome.
• Partial desensitisation of Tregs might help explain why some participants in previous tri-
als with daily dosing regimens did not respond to aldesleukin, suggesting that in future
trials the drug should not be administered on a daily basis.
Introduction
Type 1 diabetes (T1D) is the secondmost common chronic disease of children, and yet insulin
replacement is the only therapy currently approved to treat the disease. Insulin replacement
corrects insulin deficiency and hyperglycaemia but does not treat the underlying autoimmune
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T lymphocyte–mediated destruction of the insulin-producing β cells of the pancreatic islets [1].
The result is a lifelong requirement for intensive insulin treatment that increases the risk of
hypoglycaemia and stops the majority of patients from achieving adequate metabolic control
to prevent the long-term complications of retinopathy, neuropathy, and/or nephropathy [2,3].
Given these clinical outcomes, there have been intensive efforts over the last four decades to
develop immunotherapies that suppress β cell autoimmunity in order to preserve endogenous
insulin production, using standard trial methodologies [4–8]. While these approaches have
achieved some success, an alternative strategy to identify potential immunotherapies is to use
pathophysiological insights from human genetic associations to identify modifiable pathways
[9,10].
The interest in modulation of the IL-2 pathway as a potential T1D therapy was initiated by
mapping of a major susceptibility locus in the non-obese diabetic (NOD) mouse model to the
IL-2 gene [11]. The mechanism for T1D susceptibility in NODmice was identified as a reduc-
tion of regulatory T cell (Treg) function through reduced IL-2 production by the NOD suscep-
tibility allele [12]. In humans, allelic variation of the IL-2 receptor gene, IL2RA, encoding the α
subunit (CD25) was identified as a susceptibility determinant for T1D [13]. Genome-wide
association studies identified a number of other T1D susceptibility genes in the IL-2 pathway,
encoding critical proteins mediating immune activation and regulation (IL-2, IL-21, BACH2,
PTPN2, IL-10) [14,15]. Analysis of the effect of the common susceptibility allele of the major
causal variant in the IL2RA region showed that it decreased expression of CD25 on the surface
of CD4+ effector T cells (Teffs) and Tregs [16,17]. Furthermore, the IL2-IL21 T1D susceptibil-
ity region has been found to be associated with decreased numbers of IL-10 producing islet-
specific CD4+ Teffs [18]. Thus, deficiencies in the IL-2 pathway and in genes expressed in
CD4+ T cells, including Tregs, could contribute to disruption of the homeostatic equilibrium
between IL-2-dependent Tregs and Teffs, which produce IL-2 to sustain the Tregs and enable
them to regulate Teff activity during infections and maintain self-tolerance in health [19–23].
High-dose aldesleukin (Proleukin; recombinant human IL-2) is currently licensed for the
treatment of adults with metastatic renal cell cancer and metastatic melanoma, administered
intravenously at 600,000 IU/kg every 8 h for 5 d followed by 9 d of rest and a further two treat-
ment cycles, if clinically tolerated [24,25]. Aldesleukin at these doses induces the activation and
proliferation of Teffs and natural killer (NK) cells to destroy tumour cells. However, it was
found that high-dose aldesleukin also expands the Treg pool such that patients with melanoma
with enhanced expansion of Tregs had a worse outcome compared to those with fewer Tregs
[26]. These observations, combined with the results of several preclinical murine studies in
which aldesleukin selectively increased Tregs and prevented or reversed autoimmune diabetes,
have focused efforts on the development of low-dose aldesleukin protocols to treat T1D and
other immune disorders [27,28].
Most recently, proof of concept of the clinical benefit of low-dose aldesleukin has been
reported for chronic graft versus host disease [29,30], hepatitis-C-virus-inducedvasculitis [31],
systemic lupus erythematosus [32], and alopecia areata [33]. In T1D, a small safety study was
conducted in which relatively high doses of aldesleukin (4.5 × 106 IU, three times per week for
1 mo) were combined with rapamycin, resulting in a transient loss of endogenous insulin pro-
duction (as measured by C-peptide) in participants that was reversed on withdrawal of the
therapy [34]. This has led to discontinuation of this combination [35]. In contrast, using lower
doses of aldesleukin alone (range 0.33 × 106 to 3.00 × 106 IU) administered daily for 5 d
induced an increase in Tregs without impairment of pancreatic β cell function [36]. The treat-
ment regimen developed from this dose-finding study has now been carried forward into the
DIABIL-2 clinical trial to assess the efficacy and safety of ultra-low doses of recombinant
human IL-2 (rhIL-2) in children and adults with T1D [37].
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These studies and trials share an initial induction phase of daily or every other day rhIL-2
administration or long-term daily dosing modelled on cancer therapy and a standard approach
to drug development. In contrast, our goal is to establish a regular dosing regimen that could
be given to children and adults shortly after diagnosis of T1D over a long period of time that
maintains residual β cell function by protecting β cells from autoimmune Teffs through
improving Treg functionwithin physiological ranges. The underlying rationale is that we aim
to mimic the protection from disease afforded by the risk-reducing alleles of the IL-2 pathway
genes by establishing in experimentalmedicine studies a long-term dosing regimen that
induces and maintains a stable, steady-state increase in Tregs within the normal physiological
range, but that does not compromise immune defence against pathogens, responses to vac-
cines, or cancer immunosurveillance.This approach might avoid the potential complications
and risks associated with prolonged administration of immunosuppressive treatments that pre-
clude their use in the T1D prevention setting [38,39]. More intensive aldesleukin treatment
regimensmay be required for autoinflammatory disorders in which the tissue damage caused
by the ongoing immune response causes pathology that may be life-threatening without immu-
nosuppression, such as in systemic lupus erythematosus and chronic graft versus host disease.
In contrast, the immune systems of patients diagnosedwith T1D are relatively immunocompe-
tent, with only small differences in lymphocyte phenotypes between cases and controls
[18,40,41].
The first step in optimising the delivery of aldesleukin in T1D is to understand the kinetics
of the biological effects of a single dose in adults with T1D. Here, in the Adaptive Study of IL-2
Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D), the effects of single-dose aldesleukin
were investigated by observingmultiple biomarkers before treatment (baseline), at 90 min after
drug administration, daily for 4 d, and then intermittently for 9 wk. The study used an adaptive
design to initially estimate the Treg dose response to aldesleukin and then to identify the two
doses of aldesleukin that increase Tregs minimally (10% relative to pretreatment) or maximally
(20%) while remaining within the normal Treg frequency range.
Methods
Adaptive Study Design
The DILT1D trial was a 9-wk, single centre, non-randomised, open label, adaptive dose-finding
trial that was conducted at the National Institute for Health Research Cambridge Biomedical
Research Centre, Addenbrooke’s Hospital, Cambridge, United Kingdom. The study included
12 visits: after a screening visit, the aldesleukin dose was administered on day 0, and the partici-
pants were followed up, including blood sampling, 90 min after administration and subse-
quently on days 1, 2, 3, 4, 7, 9, 14, and 21, with a final follow-up visit on day 60. According to
protocol amendments, visits between the seventh and 21st days were given 48 h of flexibility,
and a safety visit on day 5 was removed. During protocol development, statistical simulations
suggested that a sample size of 40 would give an informative estimate of the dose and target
responses. The trial consisted of two phases: a learning phase (with ten individuals) and an
adaptive phase (with 30 individuals). In the learning phase, participants received 0.04 × 106,
0.16 × 106, 0.60 × 106, 1.00 × 106, and 1.50 × 106 IU/m2 of aldesleukin in ascending order, with
each dose administered to two participants before escalation. Once the tenth participant had
completed 7 d of follow-up, the clinical Treg and safety data were extracted from the trial data-
base, and a preplanned interim analysis was carried out by the clinical trial statisticians by fit-
ting a candidate set of parametric models to estimate the dose-response curve. A statistical
analysis report was generated and delivered to the Dose DeterminingCommittee (DDC)—
consisting of a physician (S. Neupane, M. Evans, or F. Waldron-Lynch), a statistician
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(M. Evangelou, S. Bond, or A. P. Mander), and a scientist (J. A. Todd or L. S. Wicker)—within
seven working days in order to select the doses to achieve the targeted Treg increases from
baseline of 10% (minimal Treg increase) and 20% (maximal). In the adaptive phase, as soon as
a participant had completed the day 7 visit, the accumulated data of the primary endpoint were
analysed by the statisticians of the study. The DDC then reviewed the interim analyses and
accumulated safety data before allocating the next recommended dose to the next participant
of the adaptive phase. For each model, a set of doses to assign to the next patient cohort was
identified that maximised the predicted reduction in the area of the 95% confidence region
around the two estimated target doses (i.e., minimising the determinant of the covariance
matrix) at the following interim analysis. The DDC resolved the infrequent cases where the
models recommended different sets of doses to assign. The DILT1D protocol and novel gover-
nance structures that were developed to make regular dose decisions by committee were pub-
lished prior to completion of the study and final analysis of the endpoints [42].
Primary Endpoint
The primary endpoint is based on the percentage of CD4+ Tregs (defined as CD3+CD4+
CD25highCD127low) within the CD3+CD4+ T cell gate following treatment with aldesleukin as
measured by fluorescence-activated cell sorting (FACS). The maximum value observed in each
participant’s profile in the follow-up periodwas identified, and the percentage change from the
baseline value defined the primary endpoint.
Secondary Endpoints
The following secondary endpoints were measured following treatment with aldesleukin:
change in full blood count; change in Treg number, phenotype, and proliferation measured by
FACS; change in cytokines and soluble receptors; change in Treg cell epigenetic profile (meth-
ylation status); change in Teff number, proliferation, and phenotype measured by FACS;
change in lymphocyte subset cell number, proliferation and phenotype subsets and NK and
natural killer T cells measured by FACS; and change in metabolic control as measured by self-
monitoring of blood glucose and laboratorymeasurement of blood glucose and glycated hae-
moglobin (HbA1c) and C-peptide.
Exploratory Endpoints
The following exploratory endpoints were measured following treatment with aldesleukin:
change in intracellular T and NK cell signalling,measured in vitro by FACS; in vitro dose
response to IL-2, measured to assess changes in intracellular T cell signalling; and change in
Treg function,measured by a T cell suppression assay.
Safety Assessments
The safety and tolerability of the treatment was assessed in trial participants by clinical history,
insulin use, physical examination, temperature, blood pressure, heart rate, 12-lead electrocar-
diograms, blood glucose, HbA1c, clinical laboratory tests, and adverse event (AE) recording.
Study Participants, Consent Procedure, and Safety Assessments
Potential participants were eligible for the study if they had a T1D duration of less than 2 y,
were positive for at least one autoantibody (anti-islet cell, anti-GAD, anti-IA2, anti-ZnT8),
were aged 18 to 50 y, and were living in the European Union. The date of diagnosis of T1D was
established by referring physicians, diabetes specialist nurses, review of register records, and
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self-reporting by potential participants. Potential participants were excluded from the study if
they had a history or evidence on screening of severe organ dysfunction, unstable diabetes,
pregnancy, malignancy (within 5 y), hepatitis B or C, human immunodeficiencyvirus, organ
transplantation, and/or donation of more than 500 ml of blood in the 2 mo prior to treatment.
Potential participants interested in enrolling in DILT1D were provided with a patient infor-
mation sheet and an informed consent form to review. Individuals were given a minimum of
24 h to consider the information provided and then were contacted to determine if they
remained interested in participating in the study or if they had any further queries. Interested
potential participants were then invited to attend a visit where the Chief Investigator or dele-
gate discussed the study with the participant, who then provided written informed consent
before undergoing screening and any other trial-related procedures.
Ethical Approval, Sponsorship, and Trial Registration
The trial was sponsored by the University of Cambridge and Cambridge University Hospitals
NHS Foundation Trust. Ethical approval for the study was granted by the Health Research
Authority, National Research Ethics Service,England (approval number: 13/EE/0020) on 18
February 2013. The study was registered in the ISRCTN Registry (ISRCTN27852285) on 26
March 2013 and at ClinicalTrials.gov (NCT01827735) on 4 April 2013.
Clinical Immunophenotyping
All clinical flow cytometry (FACS) was performed following good clinical practice at the
Department of Clinical Immunology, Addenbrooke’s Hospital, Cambridge, UK, within 4 h of
phlebotomy. Operators were blinded to the aldesleukin dose allocated. A 2.6-ml sample of
peripheral whole bloodwas collected into EDTA tubes, and 50 μl was stained with specific fluo-
rochrome-conjugated antibodies at room temperature for 15 min to identify Tregs as
CD3+CD4+CD25highCD127low T cells. The clones used were anti-CD3 (clone SK7, phycoery-
thrin [PE]-Cy7-labelled; BD Biosciences), anti-CD4 (clone RPA-T4, FITC-labelled; BD Biosci-
ences), anti-CD127 (clone HIL-7R-M21, PE-labelled; BD Biosciences), anti-CD25 (clone
M-A251 and 2A3, allophycocyanin [APC]-labelled; BD Biosciences), anti-CD45RA (clone
HI100, APC-Cy7-labelled; BioLegend), and anti-CD62L (clone DREG-56, PerCP/Cy5.5-la-
belled; BioLegend). Red cells were then lysed (BD FACS Lysing Solution); the cells were washed
and resuspended in BD Cell Fix and then immediately analysed on a BD FACSCanto II flow
cytometer utilising FACSDiva software (BD Biosciences). In parallel, a whole-bloodBDMultit-
est 6-Color TBNK assay using BD Trucount Tubes according to the manufacturers’ instruc-
tions (BD Biosciences) was run to determine the relative and absolute concentration of
lymphocyte subpopulations, including T, B, and NK cells.
Mechanistic Immunophenotyping
For each participant, 30 ml of peripheral whole bloodwas collected into lithium heparin tubes
and processed according to the workflow (S1 Fig). To determine the frequencies and pheno-
types of NK and T cell subsets in whole bloodwithin 4 h of phlebotomy, multicolour FACS
was performed using the antibodies shown in S1 and S2 Tables. A full standard operating pro-
cedure is provided in S1 Materials. For surface staining, 150 μl of whole bloodwas incubated
with fluorochrome-conjugated antibodies at room temperature for 45 min. Red cells were then
lysed (BD FACS Lysing Solution), washed, and then analysed on a BD Fortessa flow cytometer.
For intracellular staining, cells were treated with Intracellular Fixation & Permeabilization
Buffer Set (eBioscience) after labelling with surface antibodies, washed twice with Permeabili-
zation Buffer, and then incubated with an intracellular antibody panel (shown in grey in
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S1 Table) at 4°C for 45 min. Samples were analysed on a BD Fortessa flow cytometer using
FACSDiva software (BD Biosciences) and FlowJo (Tree Star). Where possible, subset frequen-
cies such as percent Tregs were expressed as an average obtained from the analysis of tubes 1–6
(S1 Table). To measure the effects in vitro of aldesleukin on CD25 and CD122 expression on
lymphocyte subsets, heparinized venous blood (25 ml) from healthy volunteers was divided
into ten 2-ml aliquots. Aliquots of whole bloodwere cultured with either 50 units/ml aldesleu-
kin or medium alone (equivalent volume PBS + 2% BSA) at time points 0, 15, 30, 90, and 180
min. Samples were incubated at 37°C while being rotated at 35 degrees above horizontal. All
samples were processed at 180 min for surface staining as per the described standard operating
procedure, except that following addition of the antibody panel, samples were quenched on ice
for 2 min and incubated at 4°C to prevent ongoing stimulation. The number of participants
contributing to each secondary outcome analysis can vary due to missing data. The missing
data, with a description of the quality control process, are summarised in S2 Materials.
Cell Sorting
For in vitro functional assays, within 4 h of phlebotomy 3-ml whole blood samples were stained
with fluorochrome-conjugated antibodies (S3 Table) for 1.5 h at room temperature, followed
by the addition of 30 ml of RBC Lysis Buffer (eBioscience) for 10 min. Cells were washed and
then resuspended in 500 μl of X-VIVO 15 + 1% AB serum for cell sorting with a BD FACS
Aria II flow cytometer and FACSDiva software (BD Biosciences). CD4+ Tregs and Teffs were
sorted by the expression pattern of CD25 and CD127: Tregs were defined as CD25highC-
D127low, and Teffs (non-Tregs) as CD25low-mediumCD127low-high. Naïve and memory Teffs and
Tregs were defined using CD45RA. Central and effectormemory Teffs were defined by the
presence or absence of CD62L, respectively.
Flow Cytometric Analysis for pSTAT5
pSTAT5 staining was carried out as previously described [17]. Whole bloodwas either directly
lysed and fixed ex vivo (Lyse/Fix Buffer, BD Biosciences) or stimulated for 30 min at 37°C with
the indicated concentrations of aldesleukin diluted in X-VIVO 15 + 1% human AB serum
(Lonza), then lysed and fixed. In some instances, 300 μl of bloodwas incubated for 2 h at 37°C
alone, with anti-human-IL-2 antibody (20 μg/ml) (clone MQ1-17H12, purifiedNA/LE, BD
Biosciences) or isotype control antibody (20 μg/ml) (clone RTK2758, purifiedNA/LE, BD Bio-
sciences) prior to addition of lyse/fix buffer. After washing, cells were permeabilizedwith meth-
anol (>99.9%, Sigma-Aldrich), washed, and stained with the fluorescence-conjugated
antibodies detailed in S4 Table. Cells were acquired using a BD Fortessa flow cytometer (BD
Biosciences) using FACSDiva software. To generate normalised results per lymphocyte cell
subset for in vitro aldesleukin dose titration studies, the pSTAT5 mean fluorescence intensity
(MFI) of cells not incubated with aldesleukinwas subtracted from the pSTAT5 MFI at each
aldesleukin dose and then divided by the pSTAT5 MFI observed in the maximal response of
that cell subset.
pSTAT5 staining of aldesleukin-stimulated cryopreservedperipheral bloodmononuclear
cells (PBMCs) was carried out as previously described [43] in a batch manner, where each
batch included 14 samples from participants and two biological controls that were kept con-
stant for all experiments to enable normalisation of data influenced by day-to-day staining var-
iation. Assays were conducted using selected participants across the dose groups at relevant
time points in regard to Treg responses. PBMCs were stained with anti-CD4-APC-eFluor 780
(clone SK3, eBioscience), anti-CD25-PE (clones ZA3 and M-A251, BD Biosciences), anti-
CD45RA-PE-Cy7 (clone HI100, BioLegend), anti-FOXP3-Alexa Fluor 488 (clone 236A/E7,
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BD Biosciences) and pSTAT5 (pY694)-Alexa Fluor 647 (clone 47, BD Biosciences) for 1 h at
4–8°C. Data acquisition was performed on a BD FACSCanto II (BD Biosciences) and analysed
using FlowJo (Tree Star).
In Vitro Suppression Assays
Suppression assays were performed in selected participants with Treg responses in V-bottom 96-
well plates using cryopreservedPBMCs by coculturing 500 sorted CD4+CD25low-mediumCD127+
CD45RA− memory Teffs (mTeffs) in the presence or absence of CD4+CD25highCD127low Tregs
at various ratios (Treg:Teff 0:1 to 1:8) with 1 × 103 CD19+CD4− B cells. Samples were stimulated
with PHA (4 μg/ml; Alere) and incubated at 37°C, 5% CO2, for 6 d. Proliferation was assessed by
the addition of 0.5 μCi/well [3H] thymidine (PerkinElmer) for the final 20 h of coculture. All con-
ditions were run in 12 replicates, and proliferation readings (counts per minute [CPM]) aver-
aged. Any samples with averaged proliferation less than 1,000 CPM from the mTeff wells alone
were excluded. The percentage suppression in each culture was calculated using the following
formula: percent suppression = 100 − [(CPM in the presence of Tregs  CPM in the absence of
Tregs) × 100].
Methylation Status
The methylation status of the FOXP3 Treg-specific demethylated region (TSDR) was analysed
using a next-generation sequencingmethod that assesses the TSDR at single-base resolution
[44].
Cytokine Measurements
Plasma C-reactive protein (CRP) was measured using a custom V-PLEX Human CRP Kit
according to manufacturer’s instructions (Meso Scale Diagnostics [MSD]) and read on the
MSD Sector Imager 6000. Plasma IL-2 was measured using the MSD S-PLEXHuman IL-2
Assay [45] (limit of quantitation 2 fg/ml) at MSD. In order to convert the plasma IL-2 (fg/ml)
levels provided by MSD to plasma aldesleukin (IU/ml) levels, readings from the MSD S-PLEX
Human IL-2 Assay at 90 min after aldesleukin administration for all DILT1D participants were
compared to results from an in-house human IL-2 DELFIA-based immunoassay [46] that has
a limit of quantitation of 10 pg/ml using aldesleukin (specific activity 16.4 IU/ng) as the stan-
dard curve. A linear relationship was observedbetween the two assays; a conversion of 3.4-fold
was required to convert MSD S-PLEXHuman IL-2 Assay readings to those obtained using an
aldesleukin standard curve. This conversion factor was applied to all other samples tested at
MSD, all of which had been below the limit of detection or quantification in the in-house assay.
Plasma-soluble CD25 was measured in duplicate using an in-house sandwich immunoassay as
described in [47].
Statistical Analysis
Predefinedpopulations of the study. Three populations were defined in this study: analy-
sis, evaluable, and safety. The analysis population includes all participants who received a single
dose of aldesleukinwith a follow-up period of 7 d and for whom the primary endpoint was
observed.The evaluable population includes all participants who received a single dose of alde-
sleukin, for whom the primary endpoint was observed, and who were not withdrawn from the
study on clinical grounds. The safety population includes all participants who received a single
dose of aldesleukin and were followed up for any period of time during the trial.
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Primary endpoint analysis—interimanalyses. The primary endpoint analysis was car-
ried out at all conducted interim analyses of the trial as well as at the end of the trial using all
accumulated data of the evaluable population. The aim of the primary analysis was to find the
best model that describes the dose-response curve, and to identify the doses that achieve the
minimumTreg increase (10%) and the maximum Treg increase (20%) targets selected by the
DDC of the trial. The relationship of the primary endpoint with dose was explored by fitting a
number of candidate models. The candidate models include the linear, the quadratic, the cubic,
the logistic, and the Emax (with three and four parameters). The Akaike information criterion
(AIC) and the deviance of each model were computed as measures of adequacy of fit. The pro-
posed target doses of each model, with their standard errors and with a 95% confidence inter-
val, were also computed. The primary endpoint analysis at the end of the trial was conducted
on both the evaluable and the analysis populations (S1 Analysis).
Secondaryendpoint analyses. For each time point and for each response/phenotype, two
measures were defined: the absolute change and the percentage change. The absolute change is
defined as the difference between the time point measurement and the baseline (pretreatment)
measurement. The percentage change is defined as the ratio of the aforementioned absolute
change to the baselinemeasurement. Based both on the absolute and on the percentage
change, a number of derived variables were defined, including the 90-min measurement
(where available), the day 1 measurement, and the maximum observed value from day 1 (or
from 90 min where available) to day 7 times 100. One of the key hypotheses of interest is
whether the absolute (or percentage) change at a particular time point of interest is zero. This
hypothesis was tested using a t-test statistic. Equivalently, paired t-tests were used to compare
two responses at a time point of interest, as reported in the results. The effect of dose on the
derived variables computed using the percentage change was explored by fitting both a linear
model and a cubic model. The model with the smallest AIC was chosen as the most representa-
tive model for fitting the data. A p-value of association of dose with the response was com-
puted by comparing through an analysis of variance (ANOVA) the two aforementioned
models with the model represented only by the intercept term. For cases where the linear
model was the best fit, we report both the dose coefficient and the dose p-value; for cases
where the cubic model was the best fit, we report only the dose p-value. The effect of dose on
the derived variables computed using the absolute change was explored by comparing a series
of models that included the effect of the baselinemeasurement of each tested response. The
model with the smallest AIC was chosen as the best model. For the cases where the interaction
and additive models were the best ones, they were compared with the baselinemodel for find-
ing the effect of dose. A dose p-value was calculated through ANOVA. Similarly, for the mod-
els where the dose model was the best, a dose p-value was computed by comparing the dose
model with the null model through ANOVA. For Treg CD25MFI, pSTAT5 (normalised
memory Treg) MFI, and FOXP3 MFI (CD25+FOXP3+ out of total CD4+ T cells) responses, we
were interested in understanding how their measurements changed per day. Using the per-
centage change at all time points between 90 min and day 60 (or day 3 for pSTAT5), the rela-
tionship with dose was modeled either through a linear model or through a cubic model, both
with no intercept term included. For each response, the model with the smallest AIC was cho-
sen across the tested days. The best model was used for predicting the response and a 95% con-
fidence interval around it for each time point for the two chosen doses derived from the
primary endpoint analysis.
Average response plots and summary statistics. The range of doses administered was
divided into five dose groups. These five groups are 0.040–0.045 × 106, 0.160–0.380 × 106,
0.385–0.610 × 106, 0.620–0.990 × 106, 1.00–1.50 × 106 IU/m2, with 12, 8, 9, 7, and 4 partici-
pants in the analysis population, respectively. For each time point of either the absolute
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change or the percentage change, we averaged the time measurements of the participants
within each dose group. This averaging was performed from the day 1 measurements (or from
90 min if applicable) to the day 7 measurements. For the participants whose visit on day 7 was
truncated to an alternative day (±48 h, according to protocol amendment), their day 7 mea-
surement was linearly interpolated using the closest measurements to day 7, which was subse-
quently used in the averaged response graphs. Throughout the manuscript the following
statistics are reported for each phenotype: mean (standard error [SE], range) and the number
of individuals (n).
Results
Participant Analysis Populations, Characteristics, and Study Design
DILT1D was an adaptive dose-finding study to increase Tregs as a proportion of total CD4+ T
cells within the physiological range, with a sample size of 40. In total, 45 participants were
enrolled in the study between 22 March 2013 and 15 May 2014, with the first participant
recruited on 8 April 2013. Five participants were ineligible for the study due to the absence of a
single T1D-associated antibody. Forty participants were treated with a single dose of aldesleu-
kin (Proleukin, Novartis); one participant withdrew due to the development of a norovirus
infection. Thirty-nine participants are included in the evaluable population, while 40 are
included in the safety and analysis populations (Fig 1A). The demographic characteristics and
autoantibody status at screening of the safety and analysis populations are shown in Table 1.
Participants were recruited from the European Union to the study site at the University of
Cambridge, United Kingdom, with 38 from the United Kingdom, 1 from Ireland, and 1 from
France [48]. Most participants had been recently diagnosedwith T1D (n = 36; duration 3–24
mo), with four newly diagnosed (< 3 mo). The DILT1D study team employed a response adap-
tive design, with a learning phase to find the shape of the dose-response curve and an adaptive
phase to find the two aldesleukin doses that increase the target Treg frequency by 10% and 20%
in the best statistical model (Fig 1B and 1C).
There were no differences in haematological parameters between baseline and the final visit
of participants (complete blood count, S5 Table; FACS analysis, S6 Table). Some clinical evi-
dence of an improvement in metabolic control was recorded, with a decrease in participants’
mean glucose and HbA1c, accompanied by a reduction in the dose of basal insulin, though this
may be a result of participants’ receiving a higher degree of specialist care by the trial team.
There was no evidence of a decrease in random non-fasting C-peptide or the development of
thyroid dysfunction (S7 Table).
Primary Endpoint
The primary endpoint was the maximum percentage increase from the baseline of Tregs in
each participant measured over the 7 d following treatment (Fig 2A) with adaptive dosing (Fig
2B). Tregs showed a dose response to a single administration of aldesleukin, with higher doses
leading to larger increases (Fig 2C). This relationship was analysed in several candidate models,
with the cubic model being found to be the best one to describe the dose-response curve as it
had the smallest deviance and visually fitted the data the best (S2 Analysis). Analysis of the
evaluable population for the primary endpoint found that the optimal doses of aldesleukin to
induce 10% and 20% increases in Tregs were 0.101 × 106 IU/m2 (SE = 0.078, 95% CI = −0.052,
0.254) and 0.497 × 106 IU/m2 (SE = 0.092, 95% CI = 0.316, 0.678), respectively (Fig 2C). The
lower confidence limit for the dose to increase Tregs by 10% is negative as a result of the esti-
mated target dose being close to zero.
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Safety and Tolerability
Single doses of aldesleukinwere well tolerated at all doses, with no serious AEs reported
(Table 2). Non-serious AEs were clinically graded as mild (easily tolerated), moderate
Fig 1. DILT1D study profile and adaptive design. (A) Flow chart showing the allocation of participants to the three predefined study populations:
evaluable, safety, and analysis. (B) The study was conducted in two phases, a learning phase (140 d) and an adaptive phase (240 d). Individual
participants are represented by a horizontal line, the length corresponding to the time from treatment until their final visit. In the learning phase, the
first ten participants received a 0.04 × 106, 0.16 × 106, 0.60 × 106, 1.00 × 106, or 1.50 × 106 IU/m2 dose of aldesleukin (colour represents dose
allocated) in ascending order, with each dose being administered to two participants before escalation. In the adaptive phase, the DDC (S3
Materials) met on 19 occasions to review the interim safety data and allocate doses based on the analysis of the accumulated Treg data (shaded
area) from all treated participants at that time. (C) Schematic of the study design illustrating that each participant who passed screening was
administered a single dose of aldesleukin and followed for 60 d. During the adaptive phase, Treg data for every participant up to day 7 was included
in an interim analysis and then further doses were allocated to the next participants. Treg, regulatory T cell; DDC, Dose Determining Committee.
doi:10.1371/journal.pmed.1002139.g001
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(discomfort), or severe (unable to carry out usual activities) and on their relatedness to alde-
sleukin administration (causality). There were 45 unexpectednon-serious AEs reported by 28
participants in the safety population. Sixteen had a single event, nine had two events, and three
had three or more events, all resolving without residual effects. Three events (two episodes of
Table 1. Participant characteristics and autoantibody status.
Category Characteristic N Mean (SE, Range)
Demography (n = 40) Ethnicity white 40 —
Male/female 30/10 —
Age (years) 40 30.54 (1.32, 18.35–49.08)
Body mass index (kg/m2) 40 23.88 (0.59, 16.70–32.00)
Body surface area (m2)* 40 1.91 (0.03,1.55–2.23)
Duration of disease (months) 40 10.74 (0.96, 0.86–23.70)
Autoantibody status (n = 40) Autoantibody type
Anti-islet 14 —
Anti-GAD 39 —
Anti-IA2 19 —
Anti-ZnT8 26 —
Autoantibody number
One positive antibody 11 —
Two positive antibodies 12 —
Three positive antibodies 7 —
Four positive antibodies 10 —
*DuBois formula.
SE, standard error.
doi:10.1371/journal.pmed.1002139.t001
Fig 2. Regulatory T cell primary endpoint. (A) Percentage of Tregs was defined as the percentage of CD3+CD4+CD25highCD127low cells within the
CD3+CD4+ gate measured. (B) Individual participant dose allocations and dose groups showing convergence of the study to doses that achieve the
two defined Treg targets. (C) A cubic model described the Treg dose response to aldesleukin best, with dashed lines showing the 10% and 20% Treg
targets and doses. The shaded areas represent 95% CIs. Baseline, or pretreatment, Treg (percent of CD4+ T cells): 6.60% (SE = 0.25%, range
3.50%–10.70%, n = 39). SSC-A, side-scattered light-A; Treg, regulatory T cell.
doi:10.1371/journal.pmed.1002139.g002
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nasal congestion on day 1 and one immediate injection site reaction) were assessed as related
to aldesleukin and were classified as adverse reactions.
A single participant had a severe AE that consisted of a transient self-limiting gastrointesti-
nal event commencing 30 h after administration of a dose of aldesleukin (S2 Fig). Prior to
administration of aldesleukin, clinical history, examination, and laboratory investigations were
normal, apart from a low neutrophil count (2.3 × 109/l [normal range: 4 × 109/l to 11 × 109/l]).
The clinical presentation and course were consistent with a norovirus infection. To confirm
the clinical diagnosis and identify the pathogen, we carried out serology testing for antibodies
to norovirus and detected the induction of GII.4 IgG antibody titres at day 9 (S2 Fig), peaking
at day 21 post-infection and declining thereafter, confirming that the participant had been
infected with norovirus.
Most participants had an expectedAE at the injection site consisting a non-itchy, local (1–5
cm), non-painful erythematous rash on day 1 followed by a subcutaneous nodule on day 2 that
resolved on average by day 10 (SE = 2, range 1–58 d; S3 Fig). Aldesleukin had no effect on
renal, bone, or liver biochemistries during the study (S8 Table).
Secondary and Exploratory Endpoints
Transient decrease in lymphocytes in blood. Full blood count analysis stratified by
dose showed a decrease in lymphocyte count in participants treated with doses greater than
0.045 × 106 IU/m2 on day 1, with a recovery by day 2 (Fig 3A; S5 Table). To investigate if the
pretreatment lymphocyte count affected the day 1 response, a set of candidate models that
included the effects of both baseline lymphocyte count and dose was analysed. The change in
lymphocyte count was found to be associated with dose through a model that depended both
on baseline lymphocyte count and dose (n = 39, dose p = 0.006; Fig 3B), with the negative
relationship to baseline lymphocyte count meaning that the higher the pretreatment lym-
phocyte count, the greater the reduction in count on day 1 (S3 Analysis). The greatest
decrease in lymphocytes was observed in participants who received the highest doses
(1.0 × 106 and 1.5 × 106 IU/m2; n = 4), with one participant developing a transient asymp-
tomatic lymphopenia (count< 1 × 109/l) that resolved by day 2. The white blood cell and
neutrophil count decreased on average by approximately 10% on day 1, without a dose
Table 2. Summary of non-serious adverse events and reactions (safety population).
Type of AE Category Details N
Unexpected AEs and reactions (n = 45) Grade
Mild 39
Moderate Common cold (2), asthma exacerbation (1), hand abrasion (1), headache (1) 5
Severe Norovirus infection (1) 1
Relatedness to aldesleukin
Unrelated 31
Unlikely 11
Possibly* Nasal congestion (2) 2
Almost certainly* Acute site reaction (1) 1
Expected AEs–injection site reaction (n = 45) Erythema 38
Nodule 29
Values in parentheses are the numbers within each category detail.
*Adverse reaction.
AE, adverse event.
doi:10.1371/journal.pmed.1002139.t002
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response, while the monocyte and basophil counts were unchanged by aldesleukin treatment
(S5 Table).
Early transient increase in eosinophils related to aldesleukindose and pretreatment
count. There was an asymptomatic decrease in eosinophils of approximately 15% at 90 min,
followed by an increase on day 1 that resolved by day 3–4, with six participants developing a
transient eosinophilia (count> 0.4 × 109/l) (Fig 4A; S5 Table). Given the increase and develop-
ment of eosinophilia, we analysed the eosinophil counts further to explore if the change was
related to both dose and baseline eosinophil count. We found that the change in eosinophil
count on day 1 was dependent on the additive effects of dose through a model that included
both baseline eosinophil count and dose effects (n = 39, dose p = 0.026; Fig 4B). We found that
the relationship was positive with a higher pretreatment eosinophil count, resulting in a greater
increase in eosinophils on day 1.
Rapid circulatory changes in regulatoryT cell numbers. Utilising clinical grade FACS
assays, we observed a rapid decrease on day 1 after aldesleukin administration in the frequency
of Tregs (Fig 5A; S6 Table) and in Treg numbers (Fig 5B). This decrease was followed by
increases in Tregs over baseline, reaching a maximum by day 3 (SE = 0.31 d, range 1–7 d,
n = 39), and then a gradual return to, or towards, baseline by day 7 for most participants. At
the highest doses, there were transient decreases in the counts of CD8+ T cells, B lymphocytes
(CD19+CD3−), and NK cells (CD3−CD56+CD16+CD19−) on day 1, recovering to baseline by
day 4 (S4 Fig).
Mechanistic studies were performed in parallel with the clinical grade FACS measurements
(Fig 5C), with strong agreement between the measurements of Treg frequency from the two
independent sources (n = 377, t-test p = 2.2 × 10−16; S5 Fig). Henceforth, the data generated by
these mechanistic assays are presented, unless otherwise stated.
Fig 3. Lymphocyte responses to a dose of aldesleukin. (A) Average response curves of the absolute change in lymphocyte count
across the five dose groups (average baseline lymphocyte count 1.78 × 109/l, SE = 0.08, range 0.95–3.84, n = 39). (B) Three-
dimensional plot of dose, baseline lymphocyte count, and change in lymphocyte count on day 1, with lines representing the vertical
projections of points (coloured by dose) on the dose/baseline lymphocyte count axis. The surface grid represents the regression model
for change in lymphocyte count on day 1 (colour scale), showing that the decrease in lymphocytes depends both on dose and
pretreatment count.
doi:10.1371/journal.pmed.1002139.g003
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Measurement of Tregs in whole blood samples after 90 min revealed that the reduction was
rapid and sustained, with Treg percentage remaining below baseline on day 1 at all doses
greater than the lowest dose range (Fig 5C). At 90 min the decline in Tregs was not dose depen-
dent, but by day 1, the reduction in Tregs was dose dependent, with higher doses of aldesleukin
leading to greater declines in Tregs (n = 37, dose p = 1.32 × 10−5; Fig 5D).
Using a recently developed IL-2 assay that is 5,000-fold more sensitive than conventional
assays, we established that baseline levels of IL-2 in the DILT1D participants were 12.17–64.07
fg/ml (0.0007–0.0036 IU/ml) (Fig 5E), similar to those reported for healthy individuals [45]. At
90 min following subcutaneous dosing, which is near the time of peak blood concentration of
aldesleukin using this route of administration [49], IL-2 plasma levels ranged from 0.35 to
27.46 IU/ml depending on the dose delivered and averaged 5.73 IU/ml (SE = 1.07, n = 37) (Fig
5E). There was a linear relationship between the dose of aldesleukin administered and the
plasma concentration of IL-2 at day 1 in vivo (Fig 5F). All aldesleukin doses produced IL-2
blood levels at 90 min sufficient to increase pSTAT5 in a portion of Teffs and NK CD56bright
(CD56highTCRα/β−) cells in addition to a majority of the Tregs (Fig 5G); this finding was con-
firmed by assessing pSTAT5 levels in various cell types ex vivo at 90 min following aldesleukin
dosing. Aldesleukin plasma levels remained above the 0.015 IU/ml concentration required to
cause signalling in naïve Tregs (nTregs) and memory Tregs (mTregs) for up to 4 d, and above
the 0.24 IU/ml concentration required for mTeff and NK CD56bright cell activation for up to 1
d, depending on dose. Thus, although Tregs have an approximately 10-fold higher affinity for
aldesleukin than do Teffs and NK CD56bright cells, a completely Treg-specific aldesleukin
plasma level was not achieved, even at the lowest doses administered.
Change in Treg phenotype. In order to determine if there was a change in Treg phenotype
in blood after treatment, we analysed expression of CD25 and CD122 on Tregs before and after
treatment. At baseline, mTregs have approximately on average a 55% higher expression of
Fig 4. Eosinophil response depends on baseline counts and aldesleukin dose. (A) Eosinophil counts showed an initial transient
decrease at 90 min in a hyperacute response to aldesleukin followed by a dose-dependent increase on day 1, with a return to baseline
by day 3–4 (average baseline eosinophil count 0.15 × 109/l, SE = 0.03, range 0.04–0.86, n = 39). (B) Three-dimensional plot of dose,
baseline eosinophil count, and change in eosinophil count on day 1, with lines representing the vertical projections of points (coloured
by dose) on the dose/baseline eosinophil count axis. The change in eosinophil count is affected by both dose and baseline eosinophil
count using a linear dose-response model, with the grid showing the regression model (colour scale) for increase in eosinophils on day
1 (colour scale) (absolute change in eosinophil count on day 1 = −0.0058 + [0.0693 × dose] + [0.1748 × baseline]).
doi:10.1371/journal.pmed.1002139.g004
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CD25 and a 90% higher expression of CD122 than nTregs (S6 Fig). Because of this heterogene-
ity betweenTreg subsets, mTregs and nTregs were assessed separately as well as together as
total Tregs. At higher aldesleukin doses there were initial small decreases of CD25 expression
on mTregs at 90 min (Fig 6A), followed by a large dose-dependent increase on day 1 in
response to treatment (n = 37, dose coefficient= 35.24, dose p = 6.68 × 10−8; Fig 6B). The
increase in CD25 in total Tregs was maximal on day 1.59 (SE = 0.13, range 1–4 d, n = 37) and
was dose dependent (n = 37, dose coefficient= 35.40, p = 3.02 × 10−8; S7 Fig). A greater
increase was observed in the mTreg compared to the nTreg subset (maximum observedper-
centage change of the CD25MFI: mTreg = 43.1%, SE = 3.7%, range 1.5%–106.0%;
nTreg = 28.4%, SE = 3.0%, range 1.8%–89.2%, n = 37, t-test p = 8.15 × 10−9). This mTreg
increase was sustained over at least 4 d for doses greater than 0.045 × 106 IU/m2 (Fig 6A). In
contrast to changes observed for Treg CD25 expression, CD122 levels on the mTregs remain-
ing in the bloodwere substantially lower at 90 min post-dosing. This was dose dependent at
day 1 (n = 33, dose p = 1.17 × 10−6; Fig 6C and 6D). This lower CD122 expression was still
prevalent at day 2, with CD122 levels on mTregs returning to baseline by day 3 at all doses
except the two highest doses, 1.0 × 106 and 1.5 × 106 IU/m2, with similar changes in CD122
Fig 5. Hyperacute regulatory T cell response to aldesleukin. (A) Treg proportions as a percent of CD4+ T cells (average Treg level 6.6%, SE = 0.2%,
range 3.5%–10.7%, n = 39) and (B) Treg counts following injection of aldesleukin as measured by the clinical grade FACS assay in conjunction with the
BD Multitest TBNK assay are shown (average baseline Treg count 0.06 × 109/l, SE = 0.01, range 0.02–0.14, n = 39). (C) Tregs as a percent of CD4+ T
cells were measured in the mechanistic FACS assay (average Treg level 6.99%, SE = 0.27%, range 3.93%–10.74%, n = 37). (D) The decline of Tregs in
blood on day 1 fits a cubic model (shaded area presents the 95% CI, n = 37). (E) Plasma IL-2 levels following aldesleukin dosing. The dotted grey lines
mark the 0.015 and 0.24 IU/ml concentrations that are the threshold levels of aldesleukin at which Tregs, and Teffs and NK CD56bright cells, respond,
respectively. (F) Relationship between the dose of aldesleukin administered and the plasma concentration of IL-2 at day 1 in vivo. (G) Aldesleukin dose-
response curves generated in whole blood from DILT1D participants for pSTAT5 responses within individual cell populations on day 60 post-treatment
(mean with bars showing 95% CI, n = 39). (A–C) show averaged response plots across the five dose groups. (D) and (F) show the best fitted models
with 95% CI. Teff, effector T cell; Treg, regulatory T cell.
doi:10.1371/journal.pmed.1002139.g005
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observed in nTregs (S6 Fig). A rapid disappearance of surface CD122 was also observed in
vitro when Tregs were incubated with aldesleukin (S8 Fig).
We investigated if there were functional changes in the Treg subpopulations remaining in
blood after aldesleukin treatment, focusing on phenotypes that could be altered by lower
CD122 cell-surface levels. Whole blood samples at baseline and 90 min post-dosing were com-
pared for their ability to respond to aldesleukin at a concentration that saturates the high-affin-
ity IL-2 receptor (1,000 IU/ml).We found that the mTregs at 90 min responded to the high
concentration of aldesleukin in vitro with lower pSTAT5 levels compared to mTregs at baseline
(n = 36, p = 1.28 × 10−9; Fig 6E). In order to replicate and extend our findings, pSTAT5 was
measured in Treg subsets from cryopreservedPBMCs isolated at baseline and day 1 that were
incubated with 0.4 IU/ml aldesleukin to provide a submaximal stimulation. In the mTreg
subset we observed that dosing with aldesleukin resulted in a transient dose-dependent
decrease in the percentage of mTregs that became pSTAT5+ on day 1 post-dosing (n = 21, dose
p = 9.60 × 10−4; Fig 6F). In contrast, although nTregs did show a reduction in pSTAT5 at 90
min after administration of aldesleukin (n = 37, p = 0.0002; Fig 6G), it was less profound than
Fig 6. Phenotypes of the residual circulating regulatory T cells at day 1. (A and B) CD25 expression was increased on mTregs (average baseline
CD25 MFI on mTreg = 7,412, SE = 181, range 5,119–9,393, n = 37). (C and D) Concurrently, there was a dose-dependent reduction in CD122 on
mTregs in blood (baseline CD122 MFI on mTreg = 444.2, SE = 14.0, range 288.0–616.0, n = 33). (E) There was a reduction in pSTAT5 levels in mTregs
incubated with a saturating concentration of aldesleukin (1,000 IU/ml) in vitro when assessing blood obtained 90 min after dosing of aldesleukin. (F) At
day 1 post-dosing, there was a dose-dependent reduction in the percentage of mTregs that were pSTAT5+ following incubation with 0.4 IU/ml
aldesleukin in vitro (percent of pretreatment time point mTregs that were pSTAT5+ following aldesleukin incubation: 56.25%, SE = 1.60%, range
43.23%–71.03%, n = 22). (G) There was a reduction in pSTAT5 levels in nTregs assessed 90 min post-dosing when the cells were incubated with a
saturating dose of aldesleukin (1,000 IU/ml) in vitro. (H) At day 1 post-dosing, there was not a consistent change from baseline in the percentage of
nTregs that were pSTAT5+ following incubation with 0.4 IU/ml aldesleukin in vitro (baseline percent of nTregs that were pSTAT5+ following incubation
with 0.4 IU/ml aldesleukin: 58.01%, SE = 1.65%, range 40.83%–69.88%, n = 21). (A) and (C) show averaged response plots across the five dose
groups. (B), (D), and (E) show the best fitted models with 95% CIs. MFI, mean fluorescence intensity; mTreg, memory regulatory T cell; nTreg, naïve
regulatory T cell.
doi:10.1371/journal.pmed.1002139.g006
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that observed for mTregs, and there was not a consistent reduction in signalling when PBMCs
were stimulated with 0.4 IU/ml of aldesleukin (Fig 6H).
Sustained Treg phenotypes and functional responses. As measured by ex vivo pSTAT5
levels, mTregs were more responsive to in vivo aldesleukin treatment than nTregs at 90 min
(n = 36, t-test comparison p = 1.46 × 10−9; Figs 7A and S9). The pSTAT5 response in mTregs
at 90 min and at day 1 was related to dose, suggesting that the maximum response had been
observed (n = 36, p = 0.001, and n = 36, p = 8.32 × 10−9, respectively) (Fig 7B). The day 1 ex
vivo pSTAT5 signal could be neutralised in vitro by the addition of anti-IL-2 antibodies to the
assay (S9 Fig), which confirms that it is the aldesleukin remaining in the blood that is responsi-
ble for the elevated levels of pSTAT5 ex vivo.
Similarly, a dose-dependent relationship was found for CTLA-4 MFI (n = 31,
p = 4.92 × 10−6; Fig 7C and 7D), FOXP3 MFI (n = 33, p = 3.58 × 10−5, dose coefficient= 71.18;
Fig 7E and 7F), and Ki-67 expression (mTregs) (n = 33, p = 0.03, dose coefficient = 39.14; Fig
7G) on day 1, with maximum increases on average by day 1.61 (SE = 0.27, range 0.1–7 d),
1.74 (SE = 0.29, range 0.1–8 d), and 2.16 (SE = 0.27, range 0.1–7 d), respectively. The findings
on day 1 were consistent with an independent analysis of cryopreservedPBMCs from day 3
post-dosing, when the Treg count in the blood is greatest. The circulatingmTregs and nTregs
are more responsive to aldesleukinwith higher CD25 (n = 15, p = 3.76 × 10−5, and n = 15,
p = 2.83 × 10−6, respectively; S9 Fig) and FOXP3 (n = 15, p = 0.01, and n = 15, p = 0.005, respec-
tively; S9 Fig) expression than at baseline. The overall effect of a dose of aldesleukin on Tregs
by day 3 was to have increased the number of fully suppressive, demethylated FOXP3+ Tregs,
which we presume have trafficked through tissues and been activated by self-antigens (Fig 7H,
7I and 7K).
The data generated in the study was used to develop a predictivemodel for each of these Treg
responses and applied it to investigate the effects of the optimal doses of aldesleukin to induce
10% and 20% increases in Tregs, 0.101 × 106 IU/m2 and 0.497 × 106 IU/m2, respectively. At
0.101 × 106 IU/m2, Treg pSTAT5 peaks at 90 min and then returns to baseline by day 2, while
CD25MFI and Treg frequencies are increased for 3 d. The 0.497 × 106 IU/m2 dose had a more
sustained predicted response, showing elevated Treg pSTAT5 for up to 3 d and total Treg fre-
quencies not quite at baseline at 7 d, with an increase in CD25 expression for up to 7 d (Fig 7J).
Effector T cell responses. There were rapid dose-dependent changes in the proportions of
mTeffs following aldesleukin treatment, with increases at 90 min at doses less than 0.61 × 106
IU/m2 and decreases below this dose, suggesting that there may be a dose threshold for this
response (n = 37, p = 6.40 × 10−5, dose coefficient= −9.23; Fig 8A and 8B). At the two highest
doses (1.0 × 106 and 1.5 × 106 IU/m2, n = 4), there was a sustained increase in mTeffs for days
3–7 (Figs 8A and S10). pSTAT5 levels in mTeffs increased at 90 min dose-dependently (n = 36,
dose p = 2.71 × 10−7; Fig 8C). The increase in pSTAT5 remained detectable on day 1 at all
doses greater than 0.045 × 106 IU/m2, with the two highest doses giving a larger and more pro-
longed response, an observation verified by the linear dose relationship on day 1 (n = 36,
p = 6.24 × 10−4, dose coefficient= 50.58; Fig 8D). There was a transient small increase in CD69
expression at all doses 90 min post-treatment for both mTregs and mTeffs (S10 Fig). There
was a small transient reduction in IL-2 sensitivity at 90 min in mTeffs compared to Tregs, at all
doses, that returned to baseline by day 1 (n = 37, t-test p = 8.18 × 10−5; S10 Fig). There was a
rapid dose-dependent reduction in expression of CD25 on mTeffs in blood that remained
below baseline until day 3, except in participants who received the two highest doses, who had
a sustained increase above baseline from day 3 onwards (n = 37, p = 5.15 × 10−6; Fig 8E and
8F). For CD122 on mTeffs in blood, there was initially a dose-dependent decrease (n = 33,
p = 1.46 × 10−5; Fig 8G and 8H) followed by an increase on days 1–4 in participants who
received the larger doses. Similar patterns of CD25 and CD122 expression changes were
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Fig 7. In vivo regulatory T cell phenotypes and functional responses to aldesleukin. (A and B) mTregs had their maximum pSTAT5 response to
treatment at 90 min, and a detectable response was sustained for up to 4 d at the higher doses and was dose dependent on day 1 with a cubic dose
response (average baseline pSTAT5 MFI = 7.36, SE = 0.33, range 4.64–12.53, n = 36). (C–F) Following activation, mTregs had a dose-dependent
increase in CTLA-4 and FOXP3 expression, returning to baseline by day 3–4 post-dosing (mTreg CTLA-4 MFI = 1,539, SE = 65, range 877–2,411,
n = 32; and mTreg FOXP3 MFI = 1,174, SE = 68, range 580–2,009, n = 34). (G) Concurrent with these changes on day 1, there was an increase in
proliferation of mTregs in blood (baseline Ki-67+ mTreg = 15.27%, SE = 0.86%, range 7.10%–30.20%, n = 33). (H) Intracellular staining of Tregs from
whole blood for FOXP3 showed an increase in FOXP3+ Tregs on day 3 (FOXP3+ Tregs/CD4+ T cells = 6.44%, SE = 0.25%, range 4.03%–10.30%,
n = 37). (I) Analysis of FOXP3 gene demethylation on total Tregs and CD62Llow (effector memory) and CD62Lhigh (central memory) CD4+ memory T cells
sorted from whole blood at pretreatment, post-treatment (day 3), and the last visit (day 60) showing stability of this Treg phenotype. (K) Tregs expanded
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observed in vitro whenmTeffs were incubated with aldesleukin (S8 Fig). To determine if there
was evidence of proliferation of mTeffs, we measured Ki-67 and found that there was a linear
dose relationship (n = 33, p = 1.93 × 10−3, dose coefficient= 145.71; Fig 8I and 8J).
Natural killer, natural killerCD56bright, and natural killerT cell responses. Treatment
at all aldesleukin doses caused a decline of total NK cells in circulation at 90 min, with the larg-
est decrease in the NK CD56bright cells compared to the NK CD56dim (CD56lowTCRα/β−) cells
(n = 38, t-test comparison p = 1.00 × 10−10) (Figs 9A and S11). The decline in NK CD56bright
cells at 90 min was dose dependent (n = 38, dose p = 0.0005; Fig 9B). NK CD56bright cells were
the NK subset most responsive to treatment, with a greater increase in NK CD56bright cells
compared to NK CD56dim cells (n = 32, t-test comparison p = 6.83 × 10−11) (Figs 9A and S11)
and a larger pSTAT5 response (Figs 9C and S11).
At baseline, NK CD56bright cells had approximately 250%more expression of CD25 and
100%more expression of CD122 than the NK CD56dim cells (S11 Fig). Following treatment,
there was a rapid dose-dependent reduction in expression of CD25 on the NK CD56bright cells
remaining in the blood (Fig 9D and 9E; n = 37, dose p = 2.09 × 10−6), and this change was
greater than in the NK CD56dimcells at 90 min (S11 Fig; n = 37, t-test p = 5.37 × 10−9). In con-
trast to the Treg response, a substantial decrease in CD25 expression on NK CD56bright cells
was observed that remained below baseline for up to 4 d after treatment (Fig 9D). CD122 on
NK CD56bright cells transiently decreased by a much more modest amount at 90 min compared
to CD25, followed by a dose-dependent linear increase (n = 38, p = 0.02, dose coeffi-
cient = 15.10) (in contrast to CD122 on Tregs; Fig 6C) that returned to baseline by day 3 (Fig
9F and 9G). Similar patterns of CD25 and CD122 expression changes were observed in vitro
when NK CD56bright cells were incubated with aldesleukin (S8 Fig). To assess the functional
effects of treatment on NK homeostasis, the proliferation marker Ki-67 was measured and it
was observed that the greatest increase was in the NK CD56bright cells at all doses administered
(n = 30, t-test comparison p = 0.0012; Figs 9H and S11). However, in the 1.0 × 106 to 1.5 × 106
IU/m2 dose range there was a reduction in the specificity since proliferation of both NK subsets
was similar (~300% increase; Figs 9H and S11).
There was a dose-dependent change in the frequency of natural killer T cells (CD56+TCRα/β+)
cells in circulation following aldesleukin treatment, with a decrease at 90 min at doses less than
0.61 × 106 IU/m2 and little change (~10%) at higher doses. Only at the two highest doses,
1.0 × 106 and 1.5 × 106 IU/m2, was there evidence of a sustained increase (~100%), with a decline
towards baseline by day 7 (S11 Fig).
Changes in inflammatorymarkers soluble CD25 and C-reactive protein. There was a
decrease in serum soluble CD25 at 90 min followed by an increase in levels of this immune
activation marker at day 1 (S12 Fig). A linear relationship was found between dose and the per-
centage change of soluble CD25 on day 1 (n = 39, dose coefficient= 13.94, p = 0.005; S12 Fig).
The highest doses (1.0 and 1.5 × 106 IU/m2) had the longest duration of response, taking 7 d to
return to baseline.We measured CRP to determine if there was evidence of an acute phase
response following treatment and observed that there was a dose-dependent increase in CRP
on day 1, where doses greater than 0.62 × 106 IU/m2 are estimated to increase CRP greater
than 100% (S12 Fig).
in vivo at day 3 post-aldesleukin suppressed in vitro proliferation of autologous Teffs equivalently to Tregs at day in a suppression assay across the dose
range (Treg:Teff ratio) tested. Error bars in (I) and (K) represent SEs. (J) Predictive cubic models based on the study data for CD25, pSTAT5, and Treg
responses at the doses identified to increase Tregs by 10% and 20%. The error bars present the 95% confidence intervals around the predictions by
these models. CM, central memory; EM, effector memory; MFI, mean fluorescent intensity; mTreg, memory regulatory T cell.
doi:10.1371/journal.pmed.1002139.g007
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Increases in chemokine expression on Tregs. CXCR3 and CCR6 are chemokine recep-
tors that contribute to the trafficking of T cells between the circulation and tissues [50]. In
regard to the proportion of mTregs expressing CXCR3 and CCR6, we found no differences in
response to aldesleukin between chemokine-defined subsets of Tregs (S13 and S14 Figs).
Fig 8. Effects of aldesleukin on effector T cell number, phenotypes, and proliferation. (A) mTeffs were responsive to aldesleukin, with their
frequencies as a percentage of non-regulatory CD4+ T cells altered in circulation (B), resulting in opposing effects, with lower doses leading to higher
mTeff frequencies and higher doses leading to reduced frequencies (average baseline mTeff percent of non-regulatory CD4+ T cells: 61.1%, SE = 1.9%,
range 38.6%–87.4%, n = 37). (C and D) There was increased pSTAT5 in mTeffs (mTeff pSTAT5 MFI = 7, SE = 0.3, range 4–13, n = 36). Concurrently
there was a dose-dependent decrease in CD25 (average baseline mTeff CD25 MFI = 1,005, SE = 31, range 676–1,436, n = 37) (E and F) and in CD122
(MFI = 137, SE = 7, range 59–248, n = 33) (G and H). (I and J) There was a dose-dependent increase in proliferation of mTeffs as measured by an
increase in Ki-67+ mTeffs over the 7 d following treatment (baseline Ki-67+ Teffs = 2.92%, SE = 0.32%, range 0.75%–10.40%, n = 33). MFI, mean
fluorescence intensity; mTeff, memory effector T cell; Treg, regulatory T cell.
doi:10.1371/journal.pmed.1002139.g008
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However, the expression of CXCR3 was increased on a per cell basis on mTregs in a dose-
dependent manner, peaking at day 1, and maintained for greater than 4 d at the two highest
doses (n = 35, dose p = 4 × 10−3; Figs 10A, 10B and S14). CCR6 on mTregs also increased,
peaking at day one (n = 37, p = 1.48 × 10−4), and was sustained above baseline for greater than
7 d at the higher doses (Figs 10C, 10D and S14).
Discussion
Our aim is to develop an immunomodulatory therapy for T1D that increases immune regula-
tion within physiological levels to inhibit autoreactive T cells while preserving immune
responses to pathogens and cancer immunosurveillance. Such a therapy could be tested ini-
tially in newly diagnosed patients, many of whom retain sufficient insulin production to pre-
vent diabetic complications [51,52], and, if successful, lead to the treatment of autoimmunity
to prevent the metabolic diagnosis of T1D. Critical to this strategy is to first characterise the
Treg dose response, the duration, and the effects of a single ultra-low dose of aldesleukin on
the human immune system. In DILT1D we have determined the Treg dose response to a single
Fig 9. Effects of aldesleukin on NK CD56bright cell number, phenotypes, and proliferation. (A and B) NK CD56bright cells showed a rapid dose-
dependent decline, with the majority of cells not in circulation at 90 min (NK CD56bright cells percent of lymphocytes: 0.41%, SE = 0.03%, range
0.09%–0.96%, n = 38). (C) Concurrent with this decline is a dose-dependent increase in NK CD56bright cell pSTAT5 levels (baseline pSTAT5
MFI = 16.55, SE = 0.70, range 9.51–27.87, n = 37). (D and E) There was a sustained dose-dependent reduction in expression of CD25 (MFI = 642,
SE = 32, range 255–1,148, n = 38) on NK CD56bright cells and (F) a transient reduction in CD122 at 90 min (G) followed by a linear dose-dependent
increase on day 1 (baseline CD122 MFI = 6,605, SE = 213, range 3,786–9,554, n = 38). (H) The outcome of treatment was increased proliferation of
NK CD56bright cells (baseline percentage of Ki-67+ NK CD56bright cells = 9.9%, SE = 0.9%, range 3.35%–25.9%, n = 30). MFI, mean fluorescence
intensity; NK, natural killer.
doi:10.1371/journal.pmed.1002139.g009
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dose of subcutaneous aldesleukin and defined two doses required to increase Treg frequencies
by predefined amounts, in a formal clinical governance framework, with an adaptive statistical
design.
The single dose of aldesleukinwas well tolerated other than a small self-limiting injection
site reaction, a common adverse event observed in almost every treated participant except in
one, in whom there was no increase in plasma aldesleukin at 90 min following administration
of an extremely low volume dose (0.02 ml). The influenza-like syndrome (malaise, myalgia,
arthralgia, shivering, or fever) that has been observed in participants administered 5-d or daily
dosing regimens was not recorded in DILT1D [36,53], although there were two episodes of rhi-
nitis that were possibly related to drug administration. A norovirus infection developed follow-
ing treatment in a single participant who, retrospectively, was found to have been subclinically
infected before treatment and who fully recovered, mounting a robust immune response to the
virus. The early time point and intensive daily monitoring in DILT1D enabled us to establish
that lymphocyte counts have a transient dose-dependent decline on day 1 without the develop-
ment of the persistent lymphopenia that is characteristic of the high-dose aldesleukin oncology
protocols [54]. Persistent lymphopenia would not be a favourable feature of a repeat dosing
regimen, but in DILT1D we observed that the decrease in lymphocytes was dose dependent,
and a transient asymptomatic lymphopenia (count< 1 × 109/l) was observed in only a single
participant treated with the highest dose administered (1.5 × 106 IU/m2). The two doses that
DILT1D identified as increasing Tregs by 10% and 20% are ultra-low and have a low risk of
lymphopenia. In contrast, eosinophils increased on day 1 after treatment, and analysis of eosin-
ophil counts determined that the pretreatment count influenced the eosinophil response to
aldesleukin,with high baseline counts leading to a transient eosinophilia post-treatment. This
finding suggests that in future trials, participants with lower eosinophil counts could be strati-
fied to aldesleukin treatment to avoid eosinophilia.
DILT1D was a mechanistic trial designed to determine immune outcomes of treatment and
not to assess clinical efficacy [55]. Participants had no evidence of the development of a decline
in C-peptide as has been observedwith frequent administration of repeat IL-2 doses with rapa-
mycin in participants with T1D [34]. Another feature of the trial is the use of FACS analysis of
whole blood rather than cryopreservedPBMCs. Fresh whole blood facilitated rapid analysis,
reduced the manipulation of the samples, and allowed the analysis of the expression of surface
receptors such as the chemokine receptors that might be lost during the freezing, storage, and
Fig 10. Aldesleukin upregulates CXCR3 and CCR6 on regulatory T cells. (A and B) Dose-dependent sustained increase in expression of CXCR3 on
mTregs (CXCR3 average baseline MFI 2252 (45.08; 1783–3193) n = 35). (C and D) The increase in CCR6 expression by mTregs was maximal and dose
dependent on Day 1 (CCR6 MFI 1523 (31; 1106–1973) n = 37). MFI, mean fluorescence intensity; Treg, regulatory T cell.
doi:10.1371/journal.pmed.1002139.g010
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thawing of PBMCs. However, due to the variation in T cell numbers in the blood between par-
ticipants, lower numbers of T cells were available for analysis in blood samples from some par-
ticipants, making it difficult to define the response in rare subsets. The DILT1D trial was
limited to adults and the analysis of peripheral blood only due to blood volume requirements
and ethical and practical considerations.
In achieving the two primary endpoints (10% and 20%maximum increases in Treg frequen-
cies from baseline), the pharmacodynamics of subcutaneous aldesleukinwere also analysed,
revealing hyperacute decreases in the frequencies of Tregs and of other cells in the blood, with
frequencies returning to, or exceeding, baseline frequencies 24 h or days later, depending on
aldesleukin dose and cell type. These decreases could be due to aldesleukin enhancing retention
of cells in the tissues and/or egress of cells from the circulation into the tissues.
In the first hours after administration of aldesleukin there was limited Treg selectivity, with
responses from Teffs and NK cells, due to high concentrations of the drug for the first few
hours, consistent with the drug’s half-life in vivo of 4–5 h following subcutaneous administra-
tion [49]. These initial IL-2 concentrations are greater than those reported in patients with sep-
sis [45]. When a conventional IL-2 assay was used and not the supersensitive IL-2 assay [46],
we observed the peak IL-2 concentrations at 90 min, but no quantifiable readings above back-
ground after this time point were measured. Use of the much more sensitive assay allowed for
the measurement of sustained physiologically active concentrations of aldesleukin up to 4 d
after dosing in the case of Tregs and between 1 and 2 d after dosing for mTeffs and NK
CD56bright cells. Nevertheless, there is still some level of Treg selectivity, and it remains to be
determinedwhat homeostasis the immune system will reach if steady-state increases of Tregs
in the order of 20%–50% are achieved by repeated aldesleukin doses, which is now being inves-
tigated in a follow-up trial, DILfrequency (NCT02265809) [56]. The finding at 24 h post-dos-
ing that the higher doses of aldesleukin (>0.38 × 106 IU/m2) resulted in sufficient
concentrations of IL-2 to stimulate Teffs and alter their circulation and proliferation should
inform the design of dosing regimens.
Another finding that impacts the design of dosing regimens came from analysis of the
expression of the IL-2 receptor subunits on Tregs, NK cells, and Teffs. There was a rapid down
modulation of the signal-transducing subunit, the β chain/CD122, on Tregs associated with a
reduction in the sensitivity of these cells to IL-2. It is possible that in a daily dosing induction
phase of IL-2 treatment, a combination of Treg desensitisation and Teff activation could
increase insulitis and exacerbate T cell/cytokine-mediateddestruction of β cells in T1D
patients. Taken together, the results suggest a regimen with doses in the range of 0.1 × 106 to
0.5 × 106 IU/m2, and we envisage that a favourable interval might be greater than every 2 d, but
probably not as much as 1 or 2 wk, if a steady-state Treg increase is the aim. Desensitisation
could partly explain the non-responsiveness of Tregs in some patients receiving daily doses of
aldesleukin of 1.0 × 106 IU/m2 or more [36]. We acknowledge that regular dosing to achieve
steady-state increases of Tregs of 20%–50%, if this is achievable in DILfrequency, may not pre-
vent β cell destruction, and a phase 2 clinical trial to test efficacywill be required to answer this
question.
The prolonged, dose-dependent duration of Treg response to a single dose of aldesleukin
was unexpected.At the higher doses of aldesleukin,mTregs remained elevated for greater than
7 d in the absence of IL-2 plasma levels above baseline, suggesting that trafficking through tis-
sues and exposure to self-antigens helps to sustain the Treg increase. Exposure of Tregs to IL-2
in vitro is not sufficient to cause proliferation. Activation and cell division of Tregs requires
antigen and T cell receptor signalling. In mouse lymph nodes removal of either T cell receptor
signalling or the IL-2 supplied from Teffs leads to reduced Treg function and uncontrolled
Teffs [22].
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Finally, in addition to the effects on Tregs by aldesleukin,we observed that NK cells that
express high levels of CD56 and CD122 and low levels of CD25 are highly sensitive to aldesleu-
kin in vivo. These NK CD56bright cells could have immunoregulatory function, so their
induction by aldesleukinmay be a desirable phenotype in suppression of T-cell-mediated auto-
immunity [57] and perhaps also in the regulation of the Teff responses that were observed
when plasma aldesleukin concentrations were high.
Having found an aldesleukin-inducedalteration in cell trafficking,we noted that a decline
in T cells from the peripheral blood has also been reported in clinical trials of teplizumab
(humanised non-Fc-binding antibody to anti-CD3), which has been shown to preserve C-pep-
tide in newly diagnosedT1D participants [4,58]. This T cell response has been characterised in
a humanised mouse model and was shown to require migration of CCR6+ CD4+ T cells to the
gut to acquire a regulatory phenotype, including increasedCCR6 expression and IL-10 produc-
tion by FOXP3+ Tregs [59]. Endogenous IL-2 production in response to anti-CD3 treatment
was reported in the original preclinical NODmouse study [60], and plasma IL-2 was increased
in a portion of participants in the clinical trials of teplizumab in T1D, accompanied by an
increase of CD25+CD4+ T cells [61]. Therefore it seems possible that anti-CD3-induced Treg
migration during treatment may be due in part to IL-2 production by anti-CD3-stimulated T
cells in vivo.
The DILT1D trial has characterised the effects of single ultra-low doses of aldesleukin on
circulating immune cells and defined two doses that increased Tregs within the normal range.
The next step in our systematic experimentalmedicine approach is to bring these two doses
forward in a second adaptive study to determine the optimal dose and frequency of administra-
tion to reach a homeostatic increase in Tregs while minimising Teff activation [56]. We do not
think this can be modelled, given the pleiotropic response to aldesleukin observed, and has to
be determined using an efficient statistical design, with mechanistic analyses to characterise the
effects of repeated doses of aldesleukin on the immune system.
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